The use of micelles to deliver potential hedgehog pathway inhibitor for the treatment of liver fibrosis

被引:25
|
作者
Kumar, Virender [1 ]
Dong, Yuxiang [1 ]
Kumar, Vinod [1 ]
Almawash, Saud [1 ]
Mahato, Ram I. [1 ]
机构
[1] Univ Nebraska Med Ctr, Dept Pharmaceut Sci, 986025 Nebraska Med Ctr, Omaha, NE 68198 USA
来源
THERANOSTICS | 2019年 / 9卷 / 25期
关键词
Liver fibrosis; Hedgehog; MDB5; GDC-0449; HEPATIC STELLATE CELLS; POLYMERIC MICELLES; OSTEOPONTIN; BIODISTRIBUTION; ACTIVATION; EXPRESSION; MIRNA; YAP; PHARMACOKINETICS; MATRIX;
D O I
10.7150/thno.38913
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Rationale: Hedgehog (Hh) pathway plays an essential role in liver fibrosis by promoting the proliferation of hepatic stellate cells (HSCs) by enhancing their metabolism via yes-associated protein 1 (YAP1). Despite the presence of several inhibitors, Hh signaling cannot be controlled exclusively due to their poor efficacy and the lack of a suitable delivery system to the injury site. Therefore, it is rationale to develop new potent Hh inhibitors and suitable delivery carriers. Methods: Based on the structure and activity of Hh inhibitor GDC-0449, we replaced its sulfonamide group with two methylpyridine-2yl at amide nitrogen to synthesize MDB5. We compared the Hh pathway inhibition and anti-fibrotic effect of MDB5 with GDC-0449 in vitro. Next, we developed MDB5 loaded micelles using our methoxy poly(ethylene glycol)-blockpoly(2-methyl-2-carboxyl-propylene carbonate-graft-dodecanol (PEG-PCC-g-DC) copolymer and characterized for physicochemical properties. We evaluated the therapeutic efficacy of MDB5 loaded micelles in common bile duct ligation (CBDL) induced liver fibrosis, mouse model. We also determined the intrahepatic distribution of fluorescently labeled micelles after MDB5 treatment. Results: Our results show that MDB5 was more potent in inhibiting Hh pathway components and HSC proliferation in vitro. We successfully developed MDB5 loaded micelles with particle size of 40 +/- 10 nm and drug loading up to 10% w/w. MDB5 loaded micelles at the dose of 10 mg/kg were well tolerated by mice, without visible sign of toxicity. The serum enzyme activities elevated by CBDL was significantly decreased by MDB5 loaded micelles compared to GDC-0449 loaded micelles. MDB5 loaded micelles further decreased collagen deposition, HSC activation, and Hh activity and its target genes in the liver. MDB5 loaded micelles also prevented liver sinusoidal endothelial capillarization (LSEC) and therefore restored perfusion between blood and liver cells. Conclusions: Our study provides evidence that MDB5 was more potent in inhibiting Hh pathway in HSC-T6 cells and showed better hepatoprotection in CBDL mice compared to GDC-0449.
引用
收藏
页码:7537 / 7555
页数:19
相关论文
共 50 条
  • [31] Response to the Potential and Challenges of Autophagy in the Treatment of Liver Fibrosis
    Hou, Li-Shuang
    Zhang, Bang-Le
    LIVER INTERNATIONAL, 2025, 45 (02)
  • [32] Potential use of CD133-positive bone marrow cells in the treatment of liver fibrosis
    Suetsugu, Atsushi
    Osawa, Yosuke
    Aoki, Hitomi
    Kunisada, Takahiro
    Ogata, Hisanobu
    Tsurumi, Hisashi
    Hoffman, Robert M.
    Moriwaki, Hisataka
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 220 - 220
  • [33] Cyclopamine as a potential therapeutic agent for treatment of tumors related to hedgehog pathway mutations
    Miller, SJ
    Yu, TC
    DERMATOLOGIC SURGERY, 2002, 28 (02) : 187 - 187
  • [34] Potential role of Hedgehog signaling and microRNA-29 in liver fibrosis of IKKβ-deficient mouse
    Hyun, Jeongeun
    Choi, Steve S.
    Diehl, Anna Mae
    Jung, Youngmi
    JOURNAL OF MOLECULAR HISTOLOGY, 2014, 45 (01) : 103 - 112
  • [35] Potential role of Hedgehog signaling and microRNA-29 in liver fibrosis of IKKβ-deficient mouse
    Jeongeun Hyun
    Steve S. Choi
    Anna Mae Diehl
    Youngmi Jung
    Journal of Molecular Histology, 2014, 45 : 103 - 112
  • [36] Salvianolic acid B inhibits the progression of liver fibrosis in rats via modulation of the Hedgehog signaling pathway
    Tao, Shanjun
    Duan, Renjie
    Xu, Tong
    Hong, Jiao
    Gu, Wenjie
    Lin, Aiqin
    Lian, Likai
    Huang, Haoyu
    Lu, Jiangtao
    Li, Tiechen
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2022, 23 (02)
  • [37] Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease
    Guy, Cynthia D.
    Suzuki, Ayako
    Zdanowicz, Marzena
    Abdelmalek, Manal F.
    Burchette, James
    Unalp, Aynur
    Diehl, Anna Mae
    HEPATOLOGY, 2012, 55 (06) : 1711 - 1721
  • [38] Potential Efficacy of Proteasome Inhibitor, Delanzomib, for the Treatment of Renal Fibrosis
    Sawa-Aihara, Ayano
    Hattori, Katsuji
    Nagao, Goshi
    Yamada, Yoshihisa
    Ishida, Tatsuhiro
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2023, 46 (02) : 279 - 285
  • [39] The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis
    Conforti, Franco
    Davies, Elizabeth R.
    Calderwood, Claire J.
    Thatcher, Thomas H.
    Jones, Mark G.
    Smart, David E.
    Mahajan, Sumeet
    Alzetani, Aiman
    Havelock, Tom
    Maher, Toby M.
    Molyneaux, Philip L.
    Thorley, Andrew J.
    Tetley, Teresa D.
    Warner, Jane A.
    Packham, Graham
    Ganesan, A.
    Skipp, Paul J.
    Marshall, Benjamin J.
    Richeldi, Luca
    Sime, Patricia J.
    O'Reilly, Katherine M. A.
    Davies, Donna E.
    ONCOTARGET, 2017, 8 (30) : 48737 - 48754
  • [40] THE TWEAK AND FN14 PATHWAY AS POTENTIAL MEDIATOR OF LIVER FIBROSIS
    Wilhelm, A.
    Munir, M.
    Humphreys, E.
    Adams, D.
    Burkly, L.
    Afford, S.
    Weston, C.
    GUT, 2014, 63 : A16 - A16